Ginkgo Bioworks (DNA) Short Interest Ratio & Short Volume → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free DNA Stock Alerts $1.16 +0.06 (+5.45%) (As of 03/28/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Ginkgo Bioworks Short Interest DataCurrent Short Volume262,240,000 sharesPrevious Short Volume255,720,000 sharesChange Vs. Previous Month+2.55%Dollar Volume Sold Short$283.22 millionShort Interest Ratio / Days to Cover11.9Last Record DateMarch 15, 2024Outstanding Shares2,152,396,000 sharesFloat Size1,340,000,000 sharesShort Percent of Float19.57%Today's Trading Volume26,099,482 sharesAverage Trading Volume22,659,953 sharesToday's Volume Vs. Average115% Short Selling Ginkgo Bioworks ? Sign up to receive the latest short interest report for Ginkgo Bioworks and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatDNA Short Interest Over TimeDNA Days to Cover Over TimeDNA Percentage of Float Shorted Over Time Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… Ginkgo Bioworks Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/2024262,240,000 shares $283.22 million +2.6%19.6%11.9 $1.08 2/29/2024255,720,000 shares $391.25 million +2.2%19.1%11.2 $1.53 2/15/2024250,230,000 shares $387.86 million +5.6%19.0%11.8 $1.55 1/31/2024236,910,000 shares $286.66 million +1.3%18.0%11.2 $1.21 1/15/2024233,850,000 shares $304.01 million -0.7%17.7%11.1 $1.30 12/31/2023235,500,000 shares $398.00 million -1.5%17.8%12.1 $1.69 Get the Latest News and Ratings for DNA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter. 12/15/2023239,070,000 shares $382.51 million +3.7%18.1%12.1 $1.60 11/30/2023230,480,000 shares $297.32 million +3.4%17.5%12.4 $1.29 11/15/2023222,910,000 shares $345.51 million -5.5%17.2%11.4 $1.55 10/31/2023235,940,000 shares $323.24 million +2.2%18.6%11.9 $1.37 10/15/2023230,820,000 shares $383.16 million -1.2%18.2%11.6 $1.66 9/30/2023233,540,000 shares $422.71 million -0.4%18.4%10.7 $1.81 9/15/2023234,530,000 shares $452.64 million +13.2%18.5%10.8 $1.93 8/31/2023207,170,000 shares $484.78 million +0.4%16.4%9 $2.34 8/15/2023206,330,000 shares $367.27 million -3.9%16.4%8.5 $1.78 7/31/2023214,590,000 shares $538.62 million -1.4%17.2%9.1 $2.51 7/15/2023217,710,000 shares $444.13 million -2.4%17.4%9.4 $2.04 6/30/2023223,020,000 shares $414.82 million +20.6%17.8%10.3 $1.86 6/15/2023184,920,000 shares $361.52 million +0.9%14.8%8.7 $1.96 5/31/2023183,290,000 shares $289.60 million -9.4%14.7%9.1 $1.58 5/15/2023202,240,000 shares $266.96 million +7.5%16.2%10.1 $1.32 4/30/2023188,130,000 shares $229.52 million -4.4%15.3%10 $1.22 4/15/2023196,750,000 shares $255.78 million +2.1%16.7%10.2 $1.30 3/31/2023192,710,000 shares $256.30 million +11.3%19.1%9.7 $1.33 3/15/2023173,100,000 shares $230.22 million +18.4%17.1%8.3 $1.33 2/28/2023146,150,000 shares $214.84 million +16.8%14.5%6.8 $1.47 2/15/2023125,180,000 shares $227.83 million +1.4%12.4%5.9 $1.82 1/31/2023123,490,000 shares $240.81 million -1.6%12.1%5.3 $1.95 1/15/2023125,510,000 shares $233.45 million -0.6%12.4%5.3 $1.86 12/30/2022126,250,000 shares $213.36 million +10.5%12.5%5.2 $1.69 12/15/2022114,290,000 shares $186.29 million -3.6%11.0%4.5 $1.63 11/30/2022118,570,000 shares $235.95 million -4.7%12.6%4.8 $1.99 11/15/2022124,380,000 shares $332.09 million -7.3%13.2%5 $2.67 10/31/2022134,220,000 shares $366.42 million -14.1%15.7%4.9 $2.73 10/15/2022156,300,000 shares $404.82 million -8.8%19.2%5.9 $2.59 9/30/2022171,280,000 shares $534.39 million -8.7%24.2%6.8 $3.12 9/15/2022187,610,000 shares $587.22 million +4.8%22.1%7.4 $3.13 8/31/2022179,060,000 shares $481.67 million +24.1%22.8%7 $2.69 8/15/2022144,250,000 shares $503.43 million -4.0%18.4%5.5 $3.49 7/31/2022150,270,000 shares $429.77 million +3.9%19.8%6.5 $2.86“The Stock Market’s Bull Run is Far from Over” -Barrons (Ad)Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… DNA Short Interest - Frequently Asked Questions What is Ginkgo Bioworks' current short interest? Short interest is the volume of Ginkgo Bioworks shares that have been sold short but have not yet been closed out or covered. As of March 15th, investors have sold 262,240,000 shares of DNA short. 19.57% of Ginkgo Bioworks' shares are currently sold short. Learn More on Ginkgo Bioworks' current short interest. What is a good short interest ratio for Ginkgo Bioworks? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DNA shares currently have a short interest ratio of 12.0. Learn More on Ginkgo Bioworks's short interest ratio. Which institutional investors are shorting Ginkgo Bioworks? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ginkgo Bioworks: GTS Securities LLC, Wolverine Trading LLC, Citadel Advisors LLC, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Ginkgo Bioworks? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 19.57% of Ginkgo Bioworks' floating shares are currently sold short. Is Ginkgo Bioworks' short interest increasing or decreasing? Ginkgo Bioworks saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 262,240,000 shares, an increase of 2.5% from the previous total of 255,720,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Ginkgo Bioworks' float size? Ginkgo Bioworks currently has issued a total of 2,152,396,000 shares. Some of Ginkgo Bioworks' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Ginkgo Bioworks currently has a public float of 1,340,000,000 shares. How does Ginkgo Bioworks' short interest compare to its competitors? 19.57% of Ginkgo Bioworks' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Ginkgo Bioworks: Vericel Co. (4.90%), Kymera Therapeutics, Inc. (13.63%), Recursion Pharmaceuticals, Inc. (29.70%), Sana Biotechnology, Inc. (20.93%), Neumora Therapeutics, Inc. (10.32%), Twist Bioscience Co. (20.77%), Beam Therapeutics Inc. (17.54%), Denali Therapeutics Inc. (7.48%), Fusion Pharmaceuticals Inc. (9.35%), 4D Molecular Therapeutics, Inc. (17.08%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short Ginkgo Bioworks stock? Short selling DNA is an investing strategy that aims to generate trading profit from Ginkgo Bioworks as its price is falling. DNA shares are trading up $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Ginkgo Bioworks? A short squeeze for Ginkgo Bioworks occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of DNA, which in turn drives the price of the stock up even further. How often is Ginkgo Bioworks' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DNA, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Vericel Short Interest Data Kymera Therapeutics Short Interest Data Recursion Pharmaceuticals Short Interest Data Sana Biotechnology Short Interest Data Neumora Therapeutics Short Interest Data Twist Bioscience Short Interest Data Beam Therapeutics Short Interest Data Denali Therapeutics Short Interest Data Fusion Pharmaceuticals Short Interest Data 4D Molecular Therapeutics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSE:DNA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the Markets